PTC names Matthew Klein as chief development officer; plus Cardurion, Sangamo, TCR2, Five Prime and more

Rare diseases company PTC Therapeutics Inc. (NASDAQ:PTCT) promoted Matthew Klein to chief development officer and Eric Pauwels to CBO. Klein was global head of gene and mitochondrial therapies; Pauwels was SVP and general manager of the Americas.

Cardiovascular disease company Cardurion Pharmaceuticals LLC hired Peter Lawrence as president and CEO, succeeding interim CEO Michael Mendelsohn, who will become chairman. Lawrence was president and COO of ArQule Inc. until its $2.7 billion takeout by Merck & Co. Inc. (NYSE:MRK) in January (see "Merck is Latest Pharma to Jump into Btk Race")...